Isoprostanes evoke contraction of the murine and human detrusor muscle via activation of the thromboxane prostanoid TP receptor and Rho-kinase
Local or systemic inflammation can severely impair urinary bladder functions and contribute to the development of voiding disorders in millions of people worldwide. Isoprostanes are inflammatory lipid mediators that are upregulated in the blood and urine by oxidative stress and may potentially induce detrusor overactivity. The aim of the study was to investigate the effects and signal transduction of isoprostanes in human and murine urinary bladders to provide potential pharmacological targets in detrusor overactivity. Contraction force was measured with myograph in murine and human urinary bladder smooth muscle (UBSM) ex vivo. Isoprostane 8-iso-PGE2 and 8-iso-PGF2α evoked dose-dependent contraction in murine UBSM, which was abolished in mice deficient for the thromboxane prostanoid receptor (TP-KO). The responses remained unaltered after removal of the mucosa or incubation with tetrodotoxin. Smooth muscle specific deletion of Gα12/13-protein or inhibition of Rho-kinase (ROCK) by Y-27632 decreased the contractions. In Gαq/11‐KO mice, responses were reduced and in the presence of Y‐27632 abolished completely. In human UBSM the TP agonist U-46619 evoked dose‐dependent contractions. Neither atropine, nor the purinergic receptor antagonist pyridoxalphosphate‐6‐azophenyl‐2',4'‐disulfonic acid (PPADS) decreased the effect, indicating that TP receptors directly mediate detrusor muscle contraction. 8-iso-PGE2 and 8-iso-PGF2α evoked dose-dependent contraction in human UBSM, and these responses were abolished by the TP antagonist SQ-29548 and were decreased by Y-27632. Our results indicate that isoprostanes evoke contraction in murine and human UBs, an effect mediated by the TP receptor. The G12/13-Rho-ROCK pathway plays a significant role in mediating the contraction and therefore may be a potential therapeutic target.